Evidence map›Paper›PMID 42220978›Full record

ArticleJHLT open2026

Comparison of donor-derived cell-free DNA fractions between combined heart-lung vs isolated heart or lung transplant recipients.

Shravani Pasupneti, Vincent Valentine, Hannah Mudgett, Chun-Po Steve Fan, Emerald Mann, Mingming Zhou, Ling Shen, Erik Henricksen, Kiran Khush, Paul Hanson and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shravani PasupnetiDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Vincent ValentineHouston Methodist Hospital, Houston, Texas.
Hannah MudgettDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Chun-Po Steve FanCareDx, Brisbane, California.
Emerald MannDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Mingming ZhouCareDx, Brisbane, California.
Ling ShenCareDx, Brisbane, California.
Erik HenricksenDepartment of Transplant, Stanford University School of Medicine, Stanford, California.
Kiran KhushDivision of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Paul HansonCareDx, Brisbane, California.
J W MacArthurDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California.
Deborah LevineDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Gundeep DhillonDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Donor-derived cell-free DNA (dd-cfDNA) is a validated marker of graft injury following isolated heart or lung transplantation. However, no such studies exist for heart-lung transplant (HLTx) recipients. Methods: HLTx recipients at a single center were screened for enrollment between August 2022 and September 2024. Heart transplant (HTx) and lung transplant (LTx) recipients from the same center served as comparison groups. Plasma dd-cfDNA samples were collected before surveillance bronchoscopies and clinically indicated evaluation for graft dysfunction during the first-year post-transplant. Stable patients demonstrated no evidence of rejection, infection, or injury at any time. Pulmonary function test results (PFTs) were monitored and compared. Results: In total, 92 HTx, 39 LTx, and 10 HLTx recipients were enrolled. The HLTx cohort had a significantly different dd-cfDNA profile compared to LTx and HTx (median dd-cfDNA in HLTx: 0.14, LTx: 0.34, and HTx: 0.06, Conclusions: This study indicates that dd-cfDNA could be a useful tool for monitoring allograft health following HLTx, though sample size was limited. Further research is underway to elucidate the mechanisms that account for these findings and to establish thresholds for detecting graft injury in this distinct cohort.

Indexed as

allograft injurydonor-derived cell-free DNA (dd-cfDNA)heart-lung transplant

Identifiers

PMID42220978
PMCPMC13218254

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.